Prognostic Significance of Subcarinal Station in Non-Small Cell Lung Cancer with T1 - 3 N2 Disease

Abstract

Background: Surgical resection may continue to offer the best chance of long-term survival for patients with non-small cell lung cancer (NSCLC). Generally, patients with N2 NSCLC have a poor prognosis. However, the surgical treatment of patients with N2 remains controversial as in these patients, some N2 subgroups have better prognoses than others. The objective of the current study was to evaluate the factors associated with N2, and to determine whether such factors are reliable predictors of survival. Methods: We retrospectively reviewed 142 non-small cell lung cancer patients with T1 - 3 N2 in whom a curative approach had been attempted between January 1994 and December 2003. The patients were consequently divided into four groups (NS-1, no subcarinal involvement and without N1; NS-2, no subcarinal involvement and with N1; SI-1, subcarinal involvement and without upper mediastinal site; SI-2, subcarinal involvement and with upper mediastinal site). We also evaluated two groups for N2 stations (single-station N2 versus multiple-station N2). Multivariate analysis by Cox's proportional hazards regression model was performed to identify the prognosis. Results: Lobectomy was carried out in 105 of the patients; bilobectomy in 10, and pneumonectomy in 27. The patients with T1 - 3 N2 disease showed survival rates of 34.1 % at 3 years and 24.1 % at 5 years. The overall survival rates at 3 years and 5 years were as follows: NS-1, 56.3 % and 43.2 %; NS-2, 35.4 % and 29.5 %; SI-1, 16.7 % and 0 %; SI-2, 15.4 % and 0 %, respectively. The NS-1 group had better prognoses than the other groups. There was a significant difference in survival rates within each group (p = 0.0005). In univariate analysis, the type of surgery, type of subcarinal involvement, and multiple-station N2 were significantly associated with prognosis. Multivariate analysis showed that NS-1 was only found to be an independent prognostic factor in cases of T1 - 3 N2 disease (p = 0.0018). NS-2 was not an independent factor but tended toward significance (p = 0.0681). But multiple-station N2 was not an independent factor (p = 0.1549). Conclusions: Surgery for patients with T1 - 3 N2 NSCLC might be acceptable if subcarinal lymph node metastasis is predicted to be absent.

Subcarinal lymph node - N2 disease - non-small cell lung cancer

References

• 1 Martini N, Flehniger B J, Zaman M B, Beattie E J. Results of resection in non-oat cell carcinoma of the lung with mediastinal lymph-node metastases.  Ann Surg. 1983;  198 386-397
• 2 Ishida T, Yano T, Maeda K, Kaneko S, Tateishi M, Sugimachi K. Surgery for lymphadenectomy in lung cancer three centimeters or less in diameter.  Ann Thorac Surg. 1990;  50 708-713
• 3 Naruke T. Significance of lymph node metastasis in lung cancer.  Semin Thorac Cardiovasc Surg. 1993;  5 210-218
• 4 Keller S M, Vangel M G, Wagner H, Schiller J H, Herskovic A, Komaki R, Marks R S, Perry M C, Livingston R B, Johnson D H. Eastern Cooperative Oncology Group. Prolonged survival in patients with resected non-small cell lung cancer and single-level N2 disease.  J Thorac Cardiovasc Surg. 2004;  128 130-137
• 5 Misthos P, Sepsas E, Athanassiadi K, Kakaris S, Skottis I. Skip metastases: analysis of their clinical significance and prognosis in the IIIA stage of non-small cell lung cancer.  Eur J Cardiothorac Surg. 2004;  25 502-508
• 6 Brueno R, Richards W G, Swanson S J, Jaklitsch M T, Lukanich J M, Mentzer S J, Sugarbaker D J. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival.  Ann Thorac Surg. 2000;  70 1826-1831
• 7 Mathisen D J, Wain J C, Wright C, Choi N, Carey R, Hilgenberg A, Grossbard M, Lynch T, Grillo H. Assessment of preoperative accelerated radiotherapy and chemotherapy in stage IIIa (N2) non-small cell lung cancer.  J Thorac Cardiovasc Surg. 1996;  111 123-133
• 8 Naruke T, Suemasu K, Ishikawa S. Lymph node mapping and curability at various levels of metastasis in resected lung cancer.  J Thorac Cardiovasc Surg. 1978;  76 832-839
• 9 Inoue M, Sawabata N, Takeda S, Ohta M, Ohno Y, Maeda H. Results of surgical intervention for p-stage IIIA (N2) non-small cell lung cancer: acceptable prognosis predicted by complete resection in patients with single N2 disease with primary tumor in the upper lobe.  J Thorac Cardiovasc Surg. 2004;  127 1100-1106
• 10 Ichinose Y, Kato H, Koike T, Tsuchiya R, Fujisawa T, Shimizu N, Watanabe Y, Mitsudomi T, Yoshimura M, Tsuboi M. Japanese Clinical Oncology Group. Completely resected stage IIIA non-small cell lung cancer: the significance of primary tumor location and N2 station.  J Thorac Cardiovasc Surg. 2001;  122 803-808
• 11 Tanaka F, Takenaka K, Oyanagi H, Fujinaga T, Otake Y, Yanagihara K, Ito H, Wada H. Skip mediastinal nodal metastases in non-small cell lung cancer.  Eur J Cardiothorac Surg. 2004;  25 1114-1120
• 12 Prenzel K L, Monig S P, Sinning J M, Baldus S E, Gustshow C A, Grass G, Schneider P M, Holscher A H. Role of skip metastasis to mediastinal lymph nodes in non-small cell lung cancer.  J Surg Oncol. 2003;  82 256-260
• 13 Halter G, Buck A K, Schirrmeister H, Aksoy E, Liewald F, Glatting G, Neumaier B, Muhling B, Nussle-Kugele K, Hetzel M, Sunder-Plassmann L, Reske S N. Lymph node staging in lung cancer using [18 F]FDG-PET.  Thorac Cardiovasc Surg. 2004;  52 96-101
• 14 Luketich J D, Friedman D M, Meltzer C C, Belani C P, Townsend D W, Christie N A, Weigel T L. The role of positron emission tomography in evaluating mediastinal lymph node metastases in non-small-cell lung cancer.  Clin Lung Cancer. 2001;  2 229-233
• 15 Cerfolio R J, Ojha B, Bryant A S, Bass C S, Bartalucci A A, Mountz J M. The role of FDG-PET scan in staging patients with non small cell carcinoma.  Ann Thorac Surg. 2003;  76 861-866
• 16 Annema J T, Hoekstra O S, Smit E F, Veselic M, Versteegh M I, Rabe K F. Towards a minimally invasive staging strategy in NSCLC: analysis of PET positive mediastinal lesions by EUS-FNA.  Lung Cancer. 2004;  44 53-60
• 17 Prenzel K L, Baldus S E, Monig S P, Tack D, Sinning J M, Gutschow C A, Grass G, Schnider P M, Dienes H P, Holscher A H. Skip metastasis in nonsmall cell lung carcinoma.  Cancer. 2004;  100 1909-1917
• 18 Fujimoto J, Toyoki H, Sato E, Sakaguchi H, Tamaya T. Clinical implication of expression of vascular endothelial growth factor-C in metastatic lymph nodes of uterine cervical cancers.  Br J Cancer. 2004;  91 466-469
• 19 Tamura M, Ohta Y. Serum vascular endothelial growth factor-C level in patients with primary non small cell lung carcinoma: a possible diagnostic tool for lymph node metastasis.  Cancer. 2003;  98 1217-1222